Factors associated with fibroblast growth factor 19 increment after oral glucose loading in patients who were previously admitted for coronary angiography.
We investigated factors associated with fibroblast growth factor 19 (FGF-19) increment after oral glucose loading (OGL) in human subjects. A total of 240 outpatients without known diabetes who were previously admitted for coronary angiography underwent an oral glucose tolerance test. FGF-19 increment (pg/ml) was calculated as FGF-19 2h after OGL minus fasting FGF-19. Overall, FGF-19 significantly increased after OGL (from 123 [78-201] to 141 [80-237], p=0.001). By age tertiles (≦ 54, 55-64, ≧ 65), FGF-19 significantly increased only in patients aged ≧ 65 (from 143 [98-209] to 189 [124-332], p<0.001). By glucose regulation status, FGF-19 significantly increased in patients with normal glucose tolerance (from 117 [78-211] to 153 [106-325], p=0.014) and in patients with prediabetes (from 117 [73-179] to 123 [70-204], p=0.043), but not in patients with diabetes (from 181 [102-243] to 178 [111-275], p=0.139). FGF-19 significantly increased in patients on statin treatment (from 120 [78-207] to 145 [86-264], p<0.001), but not in patients not on statin therapy (from 125 [86-196] to 128 [68-230] pg/ml, p=0.676). These findings remained significant after adjustment for confounders. FGF-19 increment after OGL was positively associated with age, and negatively associated with abnormal glucose regulation and statin treatment.